TY - JOUR
T1 - Prophylactic antiemetics for haematological malignancies
T2 - Prospective nationwide survey subset analysis in Japan
AU - Yoshida, Isao
AU - Tamura, Kazuo
AU - Miyamoto, Toshihiro
AU - Shimokawa, Mototsugu
AU - Takamatsu, Yasushi
AU - Nanya, Yasuhito
AU - Matsumura, Itaru
AU - Gotoh, Moritaka
AU - Igarashi, Tadahiko
AU - Takahashi, Tsutomu
AU - Aiba, Keisuke
AU - Kumagai, Kyoya
AU - Ishizawa, Kenichi
AU - Kurita, Naoki
AU - Usui, Noriko
AU - Hatake, Kiyohiko
N1 - Funding Information:
The study was funded by a Research Grant provided by the Public Health Research Foundation (Tokyo, Japan).
Publisher Copyright:
© 2019 International Institute of Anticancer Research. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Background/Aim: Although neurokinin-1 receptor antagonists are approved chemotherapy drugs in Japan, no nationwide surveys have been performed to validate chemotherapy-induced nausea and vomiting (CINV) guidelines in clinical practice. This study evaluated CINV in patients with haematological malignancies starting first-time chemotherapy. Patients and Methods: A nationwide CINV survey on patients with haematological malignancies was conducted at 118 institutions. Patients undergoing moderately emetic chemotherapy (n=17) and highly emetic chemotherapy (HEC; n=180) were compared. Results: Forty-one patients undergoing HEC received triple antiemetics. Female gender and young age were risk factors for early-phase nausea, while female gender remained a risk factor for late-phase nausea and vomiting. Among 125 patients receiving CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)-like regimens, complete response and complete control were increased in patients receiving triple antiemetics, compared to those with double antiemetics. Conclusion: Guideline compliance was very low. Although not statistically significant, there was a trend for reduced CINV and improved disease control for triple versus double antiemetics, suggesting that triple antiemetics should be considered for HEC, especially in young female patients with non-Hodgkin lymphoma receiving CHOP-like regimens.
AB - Background/Aim: Although neurokinin-1 receptor antagonists are approved chemotherapy drugs in Japan, no nationwide surveys have been performed to validate chemotherapy-induced nausea and vomiting (CINV) guidelines in clinical practice. This study evaluated CINV in patients with haematological malignancies starting first-time chemotherapy. Patients and Methods: A nationwide CINV survey on patients with haematological malignancies was conducted at 118 institutions. Patients undergoing moderately emetic chemotherapy (n=17) and highly emetic chemotherapy (HEC; n=180) were compared. Results: Forty-one patients undergoing HEC received triple antiemetics. Female gender and young age were risk factors for early-phase nausea, while female gender remained a risk factor for late-phase nausea and vomiting. Among 125 patients receiving CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)-like regimens, complete response and complete control were increased in patients receiving triple antiemetics, compared to those with double antiemetics. Conclusion: Guideline compliance was very low. Although not statistically significant, there was a trend for reduced CINV and improved disease control for triple versus double antiemetics, suggesting that triple antiemetics should be considered for HEC, especially in young female patients with non-Hodgkin lymphoma receiving CHOP-like regimens.
UR - http://www.scopus.com/inward/record.url?scp=85069286799&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069286799&partnerID=8YFLogxK
U2 - 10.21873/invivo.11611
DO - 10.21873/invivo.11611
M3 - Article
C2 - 31280230
AN - SCOPUS:85069286799
VL - 33
SP - 1355
EP - 1362
JO - In Vivo
JF - In Vivo
SN - 0258-851X
IS - 4
ER -